SunTrust analyst Sandy Draper raised his price target on Veeva to $150 and kept his Buy rating after its Q1 results, citing the company's "record high" new Vault clients on-boarded in the quarter as it tracked to surpass Commercial Solutions business. The analyst also cites Veeva's 27% subscription revenue growth in Q1 - the fastest in 5 quarters - along with its 26% increase in billings. Draper further contends that while Veeva's legacy products are still doing well, its new products like Vault CDMS saw a notable top 20 Pharma commitment with a company-wide-rollout.